Sponsor

Ferring Pharmaceuticals

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Ferring Pharmaceuticals appears in 67 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials67
Recruiting shown2
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
FIRMAGON® Intensive Drug MonitoringNCT05181800 · lead sponsor · 2019-08-20
COMPLETED
Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With DegarelixNCT03193645 · lead sponsor · 2017-06-27
COMPLETED
A Study to Investigate the Safety and Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal HypertensionNCT02929407 · lead sponsor · 2016-11-01
TERMINATED
Safety and Efficacy of Firmagon® (Degarelix) for InjectionNCT02886598 · lead sponsor · 2016-09-01
COMPLETED
A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate CancerNCT02726009 · lead sponsor · 2016-05-01
COMPLETED
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular DiseaseNCT02663908 · lead sponsor · 2016-04-19
TERMINATED
A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate CancerNCT02526784 · lead sponsor · 2015-12-01
COMPLETED
Pharmacokinetics of Degarelix in Chinese Patients With Prostate CancerNCT02468284 · lead sponsor · 2015-07-01
COMPLETED
Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate CancerNCT02229253 · lead sponsor · 2014-09-01
COMPLETED
Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.NCT02234089 · lead sponsor · 2014-09-01
COMPLETED
An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate CancerNCT02015871 · lead sponsor · 2014-01-01
COMPLETED
Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy InitiationNCT01729676 · lead sponsor · 2013-05-01
COMPLETED
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in ArgentinaNCT01861236 · lead sponsor · 2013-03-01
COMPLETED
One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese PopulationNCT01744366 · lead sponsor · 2013-01-01
COMPLETED
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate CancerNCT01491971 · lead sponsor · 2012-01-01
COMPLETED
A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGONNCT01234350 · lead sponsor · 2011-01-01
COMPLETED
A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).NCT01280188 · lead sponsor · 2011-01-01
COMPLETED
A Study of Degarelix in Taiwanese Patients With Prostate CancerNCT01220869 · lead sponsor · 2010-12-01
COMPLETED
Follow-up of Glypressin (Terlipressin) Clinical Efficacy in the Treatment of Bleeding Oesophageal VaricesNCT01335516 · lead sponsor · 2010-11-01
COMPLETED
A Degarelix Trial in Patients With Prostate CancerNCT01242748 · lead sponsor · 2010-10-01
TERMINATED
A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate CancerNCT01215526 · lead sponsor · 2010-10-01
COMPLETED
Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean PatientsNCT01215513 · lead sponsor · 2010-09-01
COMPLETED
Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate CancerNCT01071915 · lead sponsor · 2010-03-01
COMPLETED
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer PatientsNCT00884273 · lead sponsor · 2009-08-01
COMPLETED
A Long Term Safety Study of Degarelix in Patients With Prostate CancerNCT00967018 · lead sponsor · 2009-08-01
COMPLETED
Effectiveness and Safety of Firmagon®NCT00930319 · lead sponsor · 2009-06-01
COMPLETED
A Trial of Degarelix in Patients With Prostate CancerNCT00946920 · lead sponsor · 2009-06-01
COMPLETED
A Study of Degarelix in Patients With Prostate CancerNCT00928434 · lead sponsor · 2009-05-01
COMPLETED
Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate CancerNCT00831233 · lead sponsor · 2009-04-01
TERMINATED
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate CancerNCT00833248 · lead sponsor · 2009-04-01
COMPLETED
Intermittent Treatment With Degarelix of Patients Suffering From Prostate CancerNCT00801242 · lead sponsor · 2008-12-01
COMPLETED
Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate CancerNCT00738673 · lead sponsor · 2008-07-01
COMPLETED
Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation TherapyNCT00468286 · lead sponsor · 2007-05-01
COMPLETED
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation TherapyNCT00451958 · lead sponsor · 2007-03-01
COMPLETED
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate CancerNCT00295750 · lead sponsor · 2006-02-01
COMPLETED
Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate CancerNCT00268892 · lead sponsor · 2006-01-01
COMPLETED
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate CancerNCT00117286 · lead sponsor · 2005-03-01
COMPLETED
An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate CancerNCT00215683 · lead sponsor · 2005-02-01
COMPLETED
A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate CancerNCT00116753 · lead sponsor · 2005-01-01
COMPLETED
A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate CancerNCT00116779 · lead sponsor · 2004-02-01
COMPLETED
Dose Finding Trial With a New Treatment (Degarelix) for Prostate CancerNCT00819156 · lead sponsor · 2004-02-01
COMPLETED
Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer PatientsNCT00215657 · lead sponsor · 2003-03-01
TERMINATED
Investigation of a New Trial Drug (FE200486) in Prostate Cancer PatientsNCT00818623 · lead sponsor · 2002-11-01
COMPLETED
Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer PatientsNCT00117312 · lead sponsor · 2002-10-01
TERMINATED
Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486NCT00117949 · lead sponsor · 2002-04-01
COMPLETED
Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer PatientsNCT00245466 · lead sponsor · 2001-10-01
TERMINATED
The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate CancerNCT00819247 · lead sponsor · 2001-03-01
COMPLETED
Open-Label, Randomised Parallel-Group StudyNCT00728533 · lead sponsor
WITHDRAWN
PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)NCT07263490 · collaborator · 2024-10-21
RECRUITING
Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer PatientsNCT04340024 · collaborator · 2015-09-30
RECRUITING
Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate CancerNCT04301414 · collaborator · 2020-02-25
COMPLETED
Cardiovascular Events in GnRH Agonist vs. AntagonistNCT04182594 · collaborator · 2020-01-17
UNKNOWN
Fit-for-Fertility Multicenter Randomized Controlled TrialNCT03908099 · collaborator · 2019-04-03
ACTIVE_NOT_RECRUITING
Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer PatientsNCT03941665 · collaborator · 2019-03-25
COMPLETED
Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With DegarelixNCT03202381 · collaborator · 2017-06-26
UNKNOWN
Trial of ADT and SBRT Versus SBRT for Intermediate Prostate CancerNCT03056638 · collaborator · 2017-03-28
TERMINATED
Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.NCT03069937 · collaborator · 2017-03-01
COMPLETED
Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone AgonistsNCT02475057 · collaborator · 2015-08-01
COMPLETED
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical ProstatectomyNCT02020070 · collaborator · 2013-12-18
COMPLETED
Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate CancerNCT02440802 · collaborator · 2013-04-01
UNKNOWN

Drugs studied in this sponsor's trials

10 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Ferring Pharmaceuticals as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
degarelix45
goserelin4
bicalutamide3
goserelin acetate2
leuprolide2
abiraterone acetate1
degarelix Injection1
docetaxel1
degarelix RxCUI 475230 · Lead sponsor in 36 linked trial(s) · 0 currently recruiting 45 trials goserelin RxCUI 50610 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials bicalutamide RxCUI 83008 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials goserelin acetate RxCUI 203146 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials leuprolide RxCUI 42375 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials abiraterone acetate RxCUI 1100071 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial degarelix Injection RxCUI 1812345 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial docetaxel RxCUI 72962 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial ipilimumab RxCUI 1094833 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial placebo RxCUI 8375 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor48
collaborator19
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.